Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
Autor: | Mauricio, Dennis, Bellone, Stefania, Mutlu, Levent, McNamara, Blair, Manavella, Diego D., Demirkiran, Cem, Verzosa, Miguel Skyler Z., Buza, Natalia, Hui, Pei, Hartwich, Tobias Max Philipp, Harold, Justin, Yang-Hartwich, Yang, Zipponi, Margherita, Altwerger, Gary, Ratner, Elena, Huang, Gloria S., Clark, Mitchell, Andikyan, Vaagn, Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D. |
---|---|
Zdroj: | In Gynecologic Oncology March 2023 170:38-45 |
Databáze: | ScienceDirect |
Externí odkaz: |